We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+3.32%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.3B
AUM Growth
+$177M
Cap. Flow
+$235M
Cap. Flow %
18.05%
Top 10 Hldgs %
40.67%
Holding
213
New
103
Increased
34
Reduced
21
Closed
43

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$47.9M
2
ABBV icon
AbbVie
ABBV
+$27.8M
3
JNJ icon
Johnson & Johnson
JNJ
+$18.7M
4
LPSN icon
LivePerson
LPSN
+$16.1M
5
AZN icon
AstraZeneca
AZN
+$13.6M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$40.5M
2
BMY icon
Bristol-Myers Squibb
BMY
+$26.4M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$12.8M
4
ZYME icon
Zymeworks
ZYME
+$11.6M
5
META icon
Meta Platforms (Facebook)
META
+$10.9M

Sector Composition

Rank Sector Weight
1 Healthcare 62.55%
2 Technology 7.69%
3 Industrials 4.91%
4 Financials 2.93%
5 Consumer Discretionary 1.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMVT icon
101
Immunovant
IMVT
$7.93B
$2.54M 0.2%
158,500
-11,500
-7% -$303K
SNCE
102
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$2.47M 0.19%
12,200
+7,200
+144% +$1.57M
FNCH
103
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
$2.39M 0.18%
+5,000
New +$2.55M
CAMT icon
104
Camtek
CAMT
$6.18B
$2.38M 0.18%
79,746
-320,254
-80% -$8.59M
TIL icon
105
Instil Bio
TIL
$48.3M
$2.38M 0.18%
+4,750
New +$2.44M
INBX
106
DELISTED
Inhibrx, Inc. Common Stock
INBX
$2.3M 0.18%
114,643
+71,461
+165% +$2.09M
TMPM
107
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$2.14M 0.16%
+219,440
New +$2.24M
ALPN
108
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.1M 0.16%
198,260
– –
QSI icon
109
Quantum-Si Incorporated
QSI
$155M
$2.06M 0.16%
+172,396
New +$2.08M
WPF
110
DELISTED
Foley Trasimene Acquisition Corp.
WPF
$2.01M 0.15%
+200,000
New +$2.17M
HCAQ
111
DELISTED
HealthCor Catalio Acquisition Corp. Class A Ordinary Shares
HCAQ
$2M 0.15%
+200,000
New +$2.05M
JYAC
112
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$1.96M 0.15%
+199,028
New +$2.06M
BIIB icon
113
Biogen
BIIB
$30B
$1.9M 0.15%
+6,800
New +$1.83M
EQ icon
114
Equillium
EQ
$139M
$1.82M 0.14%
+254,184
New +$1.82M
VINC
115
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$1.81M 0.14%
4,685
+2,362
+102% +$953K
GIGGU
116
DELISTED
GigCapital4, Inc. Unit
GIGGU
$1.73M 0.13%
+175,000
New +$1.77M
CYXT
117
DELISTED
Cyxtera Technologies, Inc. Class A Common Stock
CYXT
$1.7M 0.13%
+170,937
New +$1.79M
PVLA
118
Palvella Therapeutics
PVLA
$1.99B
$1.67M 0.13%
8,125
+1,250
+18% +$273K
TOI icon
119
The Oncology Institute
TOI
$486M
$1.62M 0.12%
+162,759
New +$1.73M
MRUS
120
DELISTED
Merus
MRUS
$1.61M 0.12%
+76,992
New +$1.78M
WIX icon
121
WIX.com
WIX
$2.3B
$1.59M 0.12%
+5,700
New +$1.63M
KDNY
122
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.58M 0.12%
101,666
-100,000
-50% -$1.63M
NSTB
123
DELISTED
Northern Star Investment Corp. II
NSTB
$1.55M 0.12%
+155,367
New +$1.59M
TERN
124
DELISTED
Terns Pharmaceuticals
TERN
$1.54M 0.12%
+70,000
New +$1.53M
IMCR icon
125
Immunocore
IMCR
$1.72B
$1.53M 0.12%
+36,000
New +$1.6M
3 4
5
6 7

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2021 Portfolio in Review

As of Q1 2021, Sphera Funds Management held 213 positions worth $1.3B, up 16% from $1.13B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Sphera Funds Management deployed $235M of net new capital in Q1 2021, opening 103 new positions and adding to 34 existing holdings. Its largest new stake was Sanofi: 997,900 shares worth $49.4M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 68% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $26.4M trimmed.

  • Sphera Funds Management's largest Q1 2021 buy was Sanofi: 997,900 shares worth $49.4M.
  • Sphera Funds Management added most to AbbVie in Q1 2021, an estimated $27.8M increase.
  • Sphera Funds Management's biggest Q1 2021 reduction was Bristol-Myers Squibb, cutting an estimated $26.4M.
  • Sphera Funds Management fully exited Novartis in Q1 2021, selling an estimated $40.5M.
  • Sphera Funds Management's ten largest holdings make up 41% of its $1.3B portfolio in Q1 2021.
  • Sphera Funds Management opened 103 new positions and closed 43 in Q1 2021.
  • Sphera Funds Management's portfolio value rose 16% quarter-over-quarter to $1.3B.

Based on Sphera Funds Management's 13F filing for Q1 2021, filed 17 May 2021.